Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

366 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Genetics of alcohol and tobacco use in humans.
Tyndale RF. Tyndale RF. Ann Med. 2003;35(2):94-121. doi: 10.1080/07853890310010014. Ann Med. 2003. PMID: 12795339 Review.
Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.
Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB. Tyndale RF, et al. Mol Pharmacol. 1991 Jul;40(1):63-8. Mol Pharmacol. 1991. PMID: 1857341
The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins.
Niznik HB, Tyndale RF, Sallee FR, Gonzalez FJ, Hardwick JP, Inaba T, Kalow W. Niznik HB, et al. Among authors: tyndale rf. Arch Biochem Biophys. 1990 Feb 1;276(2):424-32. doi: 10.1016/0003-9861(90)90741-g. Arch Biochem Biophys. 1990. PMID: 2306106
The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse.
Sellers EM, Otton SV, Tyndale RF. Sellers EM, et al. Among authors: tyndale rf. NIDA Res Monogr. 1997;173:6-26. NIDA Res Monogr. 1997. PMID: 9260180 Review. No abstract available.
Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence.
Tyndale RF, Droll KP, Sellers EM. Tyndale RF, et al. Pharmacogenetics. 1997 Oct;7(5):375-9. doi: 10.1097/00008571-199710000-00006. Pharmacogenetics. 1997. PMID: 9352573
Mimicking gene defects to treat drug dependence.
Sellers EM, Tyndale RF. Sellers EM, et al. Among authors: tyndale rf. Ann N Y Acad Sci. 2000;909:233-46. doi: 10.1111/j.1749-6632.2000.tb06685.x. Ann N Y Acad Sci. 2000. PMID: 10911933 Review.
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.
Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM, Tyndale RF. Rao Y, et al. Among authors: tyndale rf. Mol Pharmacol. 2000 Oct;58(4):747-55. doi: 10.1124/mol.58.4.747. Mol Pharmacol. 2000. PMID: 10999944
Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk.
Tyndale RF, Sellers EM. Tyndale RF, et al. Drug Metab Dispos. 2001 Apr;29(4 Pt 2):548-52. Drug Metab Dispos. 2001. PMID: 11259349
Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver.
Howard LA, Micu AL, Sellers EM, Tyndale RF. Howard LA, et al. Among authors: tyndale rf. J Pharmacol Exp Ther. 2001 Nov;299(2):542-50. J Pharmacol Exp Ther. 2001. PMID: 11602665
A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption.
Tyndale RF, Pianezza ML, Sellers EM. Tyndale RF, et al. Nicotine Tob Res. 1999;1 Suppl 2:S63-7; discussion S69-70. doi: 10.1080/14622299050011831. Nicotine Tob Res. 1999. PMID: 11768189 Review.
This paper outlines how genetic variation in the CYP2A6 gene may protect individuals from becoming nicotine-dependent smokers, and if dependent, how impairment of the CYP2A6 gene function decreases the number of cigarettes consumed by smokers (Pianezza M, Sellers EM, Tyndale
This paper outlines how genetic variation in the CYP2A6 gene may protect individuals from becoming nicotine-dependent smokers, and if depend …
366 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback